Towa Pharmaceutical Co., Ltd.

Tokyo Stock Exchange 4553.T

Towa Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending March 31, 2024: 1.30

Towa Pharmaceutical Co., Ltd. Debt to Equity Ratio is 1.30 for the year ending March 31, 2024, a 2.67% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Towa Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending March 31, 2023 was 1.26, a 15.93% change year over year.
Towa Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending March 31, 2022 was 1.09, a 50.00% change year over year.
Towa Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending March 31, 2021 was 0.73, a -7.67% change year over year.
Towa Pharmaceutical Co., Ltd. Debt to Equity Ratio for the year ending March 31, 2020 was 0.79, a 7.71% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

Tokyo Stock Exchange: 4553.T

Towa Pharmaceutical Co., Ltd.

CEO	Mr. Itsuro Yoshida
IPO Date	April 5, 2004
Location	Japan
Headquarters	2-11, Shinbashi-cho
Employees	4,588
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Personal Care

Description

Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of diabetes, digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It had a portfolio of approximately 700 drug products. Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.

Key trends

Past 5 years